A Phase III Study of CS1003 in Subjects With Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Drug: CS1003+Lenvatinib; Drug: CS1003 Placebo+Lenvatinib Sponsor: CStone Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Research | Study